Effects of glipizide and metformin on serum insulin-like growth factor-1, 2 in patients with type Ⅱ diabetes mellitus / 中国临床药理学与治疗学

AimTo study the effects of glipizide and met formin on the serum IGF-1,IGF-2 in patients with type Ⅱ diabetes mellitus; Methods The effect of glipizide(n ＝ 40) and metformin(n ＝ 25) on serum IGF-1, IGF-2 in patients with type Ⅱ diabetes mellitus were compared with self- controlled study. Results In metformin-treated patients ,there were not significantly changes in fasting IGF-1 and IGF-2 concentrations, In glipizide-treated patients, there were markedly increased IGF-1 concentrations(181.8+ 104.5) vs (209.0+ 88.2) ng· ml-1(P＜0.05) while serum IGF-2 was not change. There was a significant reduction of blood glucose in two groups at the end of treatment(both P＜0.01), but C-peptide level was markedly increased(P＜0.05) only in glipizide-treatedpatients.Conclusion The changes of IGF-1 is markedly different between metformin-treated and glipizide-treated patients with type Ⅱ diabetes mellitus.

Effects of glipizide and metformin on serum insulin-like growth factor-1,2 in patients with type Ⅱ diabetes mellitus / 中国临床药理学与治疗学

Aim To study the effects of glipizide and metformin on the serum IGF_1,IGF_2 in patients with type Ⅱ diabetes mellitus;Methods The effect of glipizide(n=40) and metformin(n=25) on serum IGF_1,IGF_2 in patients with type Ⅱ diabetes mellitus were compared with self_ controlled study.Results In metformin_treated patients ,there were not significantly changes in fasting IGF_1 and IGF_2 concentrations,In glipizide_treated patients,there were markedly increased IGF_1 concentrations (181.8?104.5) vs (209.0?88.2) ng?ml-1(P

PPAR and insulin resistance / 中国药理学通报

Peroxisome proliferator activated receptor(PPAR), a member of the hormone receptor superfamily, is a key regulating factor in adipocyte differentiation and lipids metabolism. Recently, with the increased understanding of the precise mechanisms of TZD, thiazolidinedione class of insulin sensitizer, PPAR? has also been identified as the major functional receptor for the drugs. In the study of the relationship between PPAR and insulin resistance, considerable gaps appeared. TZD induced activation of PPAR? is known to promote insulin sensitivity. More interestingly, however, PPAR? +/- heterozygous mice were shown to be less susceptible to insulin resistance. These findings suggest that the relationship between PPAR activation and insulin sensitivity improvement is not simplely positively related. A better understanding of the role of PPAR in insulin action system will be critical in developing more efficacious and safe agents that act on PPAR and benefit patients with type 2 diabetes.